Features | Partner Sites | Information | LinkXpress
Sign In
AB Sciex
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.

Gout Detected from a Simple Blood Sample

By Labmedica International staff writers
Posted on 31 Oct 2013
An in vitro diagnostic test, which detects active Gout disease from samples of whole blood, has been launched in Europe.

The CE marked GoutiFind test takes a new approach to Gout diagnosis. Based on a key scientific discovery of how our immune system reacts to uric acid crystal deposition in joints, the GoutiFind test measures the cellular immune response to the deposits. No special clinical setting is required for the GoutiFind test. A fresh blood sample drawn in a physician’s office or clinical laboratory is all that is required for the GoutiFind test.

The GoutiFind test is offered throughout the EU as a diagnostic service by Boulder Diagnostics (Mellrichstadt, Germany) clinical diagnostic service laboratory. The GoutiFind test detects active Gout disease without employing the unreliable determination of the uric acid level. It therefore provides a noninvasive reliable diagnosis of Gout disease.

The GoutiFind test can replace the invasive joint puncture method for Gout detection and thus make reliable Gout diagnosis available to a much broader range of medical institutions and physician practices. The test is based on measuring the cellular immune response to a specific challenge with a Gout stimulus.

"The GoutiFind test simplifies and makes Gout diagnosis more broadly available," commented Dr. Wolfgang Pieken, CEO of Boulder Diagnostics Inc., and added, "the GoutiFind test is the second product from our technology platform that queries the trained immunity for active disease."

"At our clinical laboratory in Mellrichstadt, Germany, we now accept whole blood samples for Gout detection by the GoutiFind method," stated Dr. Anton Waldherr, laboratory physician of Boulder Diagnostics Europe GmbH.

Related Links:

Boulder Diagnostics



PERIPHERAL VISIONS INC
DiagCor Bioscience
ADVANCED INSTRUMENTS
comments powered by Disqus
Life Technologies

Channels

Genetic Tests

view channel
Image: Histopathology of Breast Adenocarcinoma, × 20 magnification (Photo courtesy of Nikon).

Serum Protein Biomarkers Detect Invasive Breast Cancer

The ability of serum protein biomarkers in conjunction with autoantibodies to distinguish between invasive breast cancer and benign breast conditions has been demonstrated. It has been estimated that... Read more

Industry News

view channel

Merck KGaA to Buy Sigma-Aldrich for USD 17 Billion

Merck KGaA (Darmstadt, Germany) will acquire Sigma-Aldrich (St. Louis, MO, USA) for USD 17 billion, expanding its business in North America and gaining exposure in Asia. All outstanding shares of Sigma-Aldrich will be acquired by Merck for USD 140 per share, which would represent a 37% premium to Sigma-Aldrich’s closing... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.